VALUE-Dx

VALUE-Dx (Value of diagnostics to combat antimicrobial resistance by optimizing antibiotic use) is an Innovative Medicines Initiative (IMI) project which aims to combat antimicrobial resistance (AMR) and improve patient outcomes.  VALUE-Dx is a unique multidisciplinary consortium, with participation of clinicians, microbiologists, health economists, social scientists, and industry, that should help to build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

For further information, please visit: https://value-dx.eu/

VALUE-Dx (Value of diagnostics to combat antimicrobial resistance by optimizing antibiotic use) is an Innovative Medicines Initiative (IMI) project which aims to combat antimicrobial resistance (AMR) and improve patient outcomes.  VALUE-Dx is a unique multidisciplinary consortium, with participation of clinicians, microbiologists, health economists, social scientists, and industry, that should help to build the medical and economic case for rapid diagnostics as a public good in the fight against antibiotic resistance.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

For further information, please visit: https://value-dx.eu/